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2Abstract
Background: Fear of recurrence (FoR) is the most frequent concern patients wish to
discuss in head and neck review clinics.
Aim: To design a simple screening question on fear of recurrence to be incorporated into
the University of Washington Quality of Life Questionnaire (UW-QOLv4), for use in
clinical practice.
Methods: A cross-sectional survey comprising 528 patients.
Results: 11% selected the two most severe FoR categories. FoR responses correlated
strongly (Spearman rs=-0.82) with the mean score of the 7 items of the Fear of Recurrence
Questionnaire. There was also a strong association with anxiety and mood dysfunction as
measured from the UW-QOL, and with overall QOL. Patients more affected by FoR
tended to be younger and post radiotherapy or chemotherapy.
Conclusion: The FoR screening question should be bolted on to the UW-QOLv4 in order
to help identify patients with significant FoR might benefit from further intervention.
3Introduction
One of the main emotional aspects for cancer survivors is the anxiety related to fear of the
cancer coming back. Fear of recurrence (FoR) is described as ‘the fear associated with the
possibility the cancer will return or progress in the same or another part of the body’. 1 Fear of
recurrence is a significant psychological problem and rates of up to 65% have been reported.
2 It is the most frequent issue patients wish to raise in review consultations. 3,4 This is not
unexpected as patients face considerable uncertainty and daily challenges of living with and
beyond head and neck cancer (HNC). 5 Although FoR is a complex issue influenced by a
multitude of factors, including demographic, clinical and psychological factors, 2 there is a
body of evidence developing in the literature specific to HNC. 5-11
It is understandable that patients feel anxious about FoR and this can be considered entirely
normal. However, sometimes the anxiety can develop into a clinical problem with symptoms
such as ruminative worry, poor concentration, poor morals, depression and poor quality of
life. A self-regulation model consisting of psychological controls on thoughts and emotions
has been developed to help explain this anxiety response in patients. It is a parallel process
model divided into 3 sections; illness representations or concerns, emotional reactions,
coping behaviours and an appraisal of he success of this coping. 12 The degree of success of
the patient’s coping is appraised and feedback to change the illness representations. The
beliefs of the patient with high fears of recurrence are such that they frequently interpret
everyday changes in bodily symptoms as a sign of serious disease. They then develop
concern for their health and fear serious illness and death; this can be very intrusive in the
patient’s life. These responses in the form of thoughts and unpleasant emotions then lead
consequentially to behaviours such as reassurance-seeking, increased medical consultations
and healthcare costs. 13, 14 Anxiety can therefore have an effect on provisions of care in cancer
as those who have a high anxiety require greater assistance and consume more health care
resources. There has also been evidence to suggest that FoR in patients does not diminish
over time so is an ongoing burden for some patients. 1, 6
It is difficult to predict which patients will experience FoR as it does not seem to relate to
routine patient characteristics, such as stage and site of disease. 6 The Patient Concerns
Inventory (PCI) gives the opportunity for FoR to be discussed in consultations as prompted
by the patient. 3,4 This facilitates the discussion of the emotional aspects of cancer. 15
4However with the PCI, there is no is no measure of severity to allow a focus on patients with
more significant problems. For these patients, signposting for additional emotional support
could be appropriate as could consideration of specific FoR intervention such as AFTER. 16
To screen for FoR there are several questionnaires available. 17,18 However, for simplicity in
clinical care it would be very useful to have a single question that could be added to an
existing health related quality of life questionnaire such as the University of Washington
questionnaire (UW-QOLv4). 19 The UW-QOL is a commonly used head and neck cancer
specific HRQOL questionnaire. Mood and anxiety were added to the original questionnaire 19
and there is merit in adding an item about FoR. Hence the aim of this study is to provide an
individual question to assess FoR in the style of the UW-QOL. This can be added to the UW-
QOL to help identify those patients with levels of FoR who might benefit from intervention.
Methods
The university hospital Aintree database was used to access the records of patients treated for
primary head and neck squamous cell carcinomas between 2008 and 2012. This gave a cohort
of 1545 patients. These patients were analysed to see if they were currently alive or dead
using both the hospital Sigma system and ONS data. Of the remaining patients those aged
over 85 were excluded from the postal survey as were any patients treated with palliative
intent or active recurrence, with cognitive impairment or living overseas and those from
previous surveys having volunteered a wish not to receive any more questionnaires. Approval
for the survey was given by Aintree University Hospital Clinical Audit Department.
The new UW-QOL style FoR question (Figure 1) was designed in several steps. The authors
formulated the initial wording. This was then discussed with patients at both the Units Head
and Neck Cancer Support Group and also a Head and Neck Cancer Research Forum.
Changes were made and emailed round to patients who were unable to attend the meetings
and also the two Head and Neck Clinical Nurse Specialists and our Emotional Support
Therapist. The final version was lastly emailed around to the group again.
The UW-QOL is scored on two subscales; physical and socio-emotional function. 20 The
physical function is scored as an average of questions based on swallowing, chewing, speech,
saliva, taste and appearance, whilst social-emotional function is the average of activity,
recreation, pain, mood, anxiety and shoulder. Criteria derived from earlier work 21 can
5indicate the domains in which patients have a significant problem or dysfunction, these
criteria being based on a mix of domain scores and domain importance over the past week.
There is also a single item overall QOL question for which patients are asked to consider not
only physical and mental health, but also other factors, such as family, friends, spirituality or
personal leisure activities important to their enjoyment of life.
The survey package included the UW-QOL version 4, the new FoR screening question, and
also a 7-item ‘Fear of Recurrence questionnaire’ 17 suitable for evaluating FoR in the
outpatient setting. The 7 questions consisted of statements with a 5-point response scale (not
at all, a little, sometimes, a lot, all the time). This was included to enable comparison of the
FoR screening question with the more detailed FoR-specific questionnaire, i.e. with a more
established measure of the levels of FoR that patients were actually experiencing.
Survey packs containing a free return envelope, the survey, a cover letter and support group
information were mailed on 28 February 2014. A reminder pack was sent to non-responders
on 12 May 2014. Incoming survey data were entered into SPSS V19 software which was
used for the analyses. Spearman correlation was used to assess the strength of association
between levels reported for FoR and items from the Fear of Recurrence Questionnaire. The
Chi-squared test or Kruskal-Wallis test was used as appropriate to compare characteristics of
patients within each FoR category, these being clinical and personal characteristics and also
dysfunction, subscale scores and overall QOL pertaining from the UW-QOL. Due to the
number of tests performed statistical significance was set at p<0.01.
Results
The survey response was 60% (528/878) of which 513 completed the single item question on
FoR. Median (IQR) age at time of first mailing for these 513 patients was 65 (58-72) years
and 71% (366) were male. Location of primary tumour was oral (35%, 181), oropharyngeal
(36%, 185), laryngeal (20%, 105) or other (8%, 42). Overall clinical stage was late (stages 3-
4) for 45% (216/481), unknown for 32. Primary treatment comprised surgery alone (40%,
201/499), surgery with adjuvant radiotherapy (42%, 211/499) or primary CT/RT (17%,
87/499), unknown for 14. Median (IQR) time from operation (or diagnosis if no operation) to
initial survey mailing was 36 (26-49) months. Analyses were performed to compare response
to the single FoR question (58%, 513/878 overall) by these clinical and personal
characteristics. There were minor variations, though response was notably lower (defined as
650% or less) for those aged under 55 years (48%, 74/154) and for those more than four years
on from treatment (50%, 137/275).
Responses to the new FoR question and to the 7 items on the more established FoR
questionnaire are summarised in Table 1. Only 5% (28) selected the most concerning
category in the new question (i.e. I am fearful all the time) and only another 5% (26) the next
severe category (I get a lot of fears of recurrence and these can really pre-occupy my
thought). Almost one third (29%, 147) responded to the middle option (I am sometimes
having fearful thoughts but I can usually manage these). Most patients though (61%, 312)
responded to the lesser FoR categories with most (49%, 249 overall) having a little fear that
didn’t really bother them and only a minority (12%, 63 overall) saying they had no fear of
recurrence. Spearman correlation was strongest between the new FoR question and
statements 1 (I am afraid that my cancer may recur, rs=-0.83, p<0.001), and 2 (I am worried
or anxious about the possibility of cancer recurrence, rs=-0.80, p<0.001) from the 7 item FoR
questionnaire and weakest with statement 6 (I examine myself to see if I have physical signs
of cancer, rs=-0.46, p<0.001) with correlation coefficients ranging in strength between rs=-
0.68 and rs=-0.75 for the other 4 statements. The mean score was computed from the
responses to each of the 7 items on the FoR questionnaire and this was also strongly
correlated (rs=-0.82, p<0.001, Figure 2) with the new FoR question.
Responses to the new FoR question showed strong association with many aspects of
dysfunction as tapped into by studying UW-QOL domain scores and importance (Table 2).
Particularly strong were the associations with anxiety and mood dysfunction. Not
unsurprisingly there was therefore stronger discrimination in regard to the social-emotional
subscale score than the physical subscale score. There was also a pronounced trend over FoR
categories in the percentage reporting good, very good or outstanding overall quality of life.
Patients reporting more severe levels of FoR tended to be younger (Table 3). There were also
significant associations with ever having had radiotherapy or chemotherapy as part of the
head and neck cancer journey. Overall clinical staging of the primary tumour, primary
tumour site and primary treatment showed little association with FoR, as did time from initial
treatment, nor the age when patients finished formal education.
7Discussion
Previous clinic outcomes research has shown that FoR is the most common issue which head
and neck cancer patients want to raise within clinic. 1,3,4 High levels of FoR can have a
detrimental effect on HRQOL. 9 FoR cannot be easily predicted by routine patient
characteristics such as gender, site and stage. 1, 4 This was also reflected in this study though
patients reporting more severe levels of FoR tended to be younger, post-radiotherapy or
chemotherapy. Without clear clinical factors to predict which patients might have FoR there
is a need to have a screening tool that can act as a prompt to allow the issue to be discussed.
The PCI provides such opportunity. 3 However once identified it would be helpful to gauge
the degree of FoR concern and to include a single screening question bolted on to a well
established HRQOL would aid simplicity. The FoR screening question used in this study was
developed in collaboration with patients and the multiprofessional team but the census group
was based just at one unit. There might be a need in future studies to assess cross-cultural
variation in the wording used. The FoR question was assessed in a cross sectional survey of
survivors. The cohort is open to survivorship bias with advance cancer being relatively under
represented and also there is no longitudinal evaluation. The response rate of 60% was
acceptable for the purpose of correlation with another fear of recurrence measure.
Using the new FoR question, a minority of patients (12%) reported 'no fear of recurrence'.
Nearly half reported 'having a little fear that didn’t really bother them'. The group where FoR
was substantial were the 5% reporting 'I am fearful all the time' and another 5% reporting 'a
lot of fears of recurrence and these can really pre-occupy my thought'. There was good
correlation between items in the single questionnaire and the 7 question FoR scale (figure 2).
Hence it would seem reasonable to suggest the choice of wording in the single UW-QOL
style FoR has reasonable validity to help grade severity and form a question that might help
screen patients with clinically meaningful FoR. These patients could have additional support
and intervention. Where to set the cut off will need further research using a larger sample
and longitudinal data but from this study it could be postulated that those patients scoring the
worse two items 'I am fearful all the time or a lot of fears of recurrence and these can really
pre-occupy my thought', should be considered for added assessment and support.
There is an association between anxiety dysfunction as measured by the UW-QOL and FoR. 1
A cut-off for anxiety dysfunction has been defined for the UW-QOL. 20 However in the
8cohort sampled in this study, 16 participants (out of 53) who selected the two highest options
of FoR in the screening question did not register as having anxiety dysfunction on the
UWQOL. This suggests there is a place for a FoR question as one third of patients within the
two most severe categories would have been missed by the anxiety question alone. The
middle option of the FoR screening question was selected by 144 patients, and 108 of these
recorded fearful thoughts without anxiety being flagged up as a significant problem, showing
that most of these patients with more moderate levels of FoR would be missed by the anxiety
question alone. This supports the inclusion of a separate FoR question and its inclusion as
part of patient-reported outcomes should enhance the clinic consultation. 22
The new FoR question also correlated strongly with the social subscale of the UWQOL 20
suggesting that FoR is a relevant social problem within head and neck cancer. However it
also correlated to a lesser extent with the physical subscale of the UWQOL suggesting that
FoR can be caused by both physical and social sources. This finding confirms that FoR can
be linked to symptom experience. That is, patients with complaints about symptoms may
think that they indicate a possible new disease process. This supports the Leventhal Self-
Regulation Model. Alternatively it could mean that greater fears of recurrence magnify the
reporting of other symptom complaints (i.e. reverse ‘causation’). The correlation with overall
quality of life score suggests this, in that patients overall well-being after cancer has an effect
on FoR.
This initial cross sectional survey has shown that this single FoR question could have merit in
the clinical care of head and neck cancer patients. Patients with FoR dysfunction can receive
extra support and if required formal intervention focused on addressing FoR (AFTER). 16
Further studies comparing the PCI and the screening question may also provide beneficial
results to determine if those patients with FoR actually wish to discuss their problems. There
is evidence that supports early intervention 22 as being most effective for FoR, so longitudinal
evaluation of both screening for FoR and intervention is essential to help ascertain the
optimal timing to support patients following completion of their cancer treatment.
Conclusion
The new FoR screening question should be bolted on to the UW-QOLv4. It would not add
any substantial questionnaire burden for patients. The inclusion of this question is important
as it not only will facilitate discussion in clinics concerning the issue of FoR, it will also
9afford the opportunity for further outcomes research into the optimal intervention aimed at
reducing FoR and improving the socio-emotional impact of cancer endured in patients during
survivorship.
.
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Figure 1. Fear of Cancer Recurrence (FoR) severity scale
Fear of the cancer coming back (Tick one box ):
 I have no fear of recurrence
 I have a little fear, with occasional thoughts but they don’t really bother me
 I am sometimes having fearful thoughts but I can usually manage these
 I get a lot of fears of recurrence and these can really preoccupy my thoughts
 I am fearful all the time that my cancer might return and I struggle with this
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Table 1. Questions about Fear of cancer Recurrence (FoR)
New Single FoR screening question
(100) I have no
fear of
recurrence


















(0) I am fearful





12% (63) 49% (249) 29% (147) 5% (26) 5% (28)
The 7 item FoR questionnaire (1) Not at all (2) A little (3) Sometimes (4) A lot (5) All the time
1. I am afraid that my cancer may recur 14% (72) 40% (205) 33% (169) 8% (41) 5% (26)
2. I am worried or anxious about the
possibility of cancer recurrence 17% (89) 39% (198) 32% (164) 7% (36) 5% (24)
3. How often have you worried about
the possibility of getting cancer again 14% (72) 37% (190) 34% (173) 10% (49) 5% (28)
4. I get waves of strong feelings about
the cancer coming back 40% (205) 29% (147) 21% (105) 6% (30) 4% (22)
5. I think about the cancer returning
when I didn't mean to 39% (200) 31% (160) 21% (105) 6% (33) 2% (11)
6. I examine myself to see if I have
physical signs of cancer 26% (132) 20% (104) 31% (158) 16% (81) 7% (36)
7. To what extent does worry about
getting caner again spill over or intrude
on your thoughts and activities
38% (193) 27% (140) 24% (121) 7% (36) 4% (20)
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Table 2. Association of new Fear of cancer Recurrence (FoR) question with UW-QOL





































%Dysfunction as measured on the UW-QOL
Pain 6% (4/63) 7% (17/248) 18% (26/146) 28% (7/25) 39% (11/28) <0.001
Activity 2% (1/63) 7% (18/248) 15% (22/146) 12% (3/25) 39% (11/28) <0.001
Recreation 2% (1/63) 5% (12/246) 4% (6/147) 8% (2/25) 36% (10/28) <0.001
Shoulder 3% (2/60) 10% (23/238) 19% (27/140) 17% (4/24) 33% (9/27) <0.001
Mood 0% (0/62) 2% (4/243) 19% (28/145) 52% (13/25) 61% (17/28) <0.001
Anxiety 0% (0/63) 1% (3/246) 25% (36/144) 60% (15/25) 79% (22/28) <0.001
Appearance 0% (0/63) 4% (10/248) 11% (16/147) 24% (6/25) 32% (9/28) <0.001
Swallowing 0% (0/62) 5% (13/248) 10% (14/147) 12% (3/25) 36% (10/28) <0.001
Chewing 0% (0/61) 4% (9/245) 9% (13/145) 8% (2/25) 18% (5/28) 0.003
Speech 3% (2/61) 4% (9/245) 8% (12/144) 4% (1/25) 29% (8/28) <0.001
Taste 3% (2/61) 8% (20/244) 10% (15/145) 12% (3/25) 29% (8/28) 0.004
Saliva 13% (8/62) 16% (38/244) 24% (34/142) 24% (6/25) 41% (11/27) 0.007
% good, very good or outstanding
overall QoL 92% (58/63) 87% (216/247) 62% (91/146) 46% (12/26) 25% (7/28) <0.001
Median (IQR) Physical function
subscale score (0-100)** 90 (80-100) 90 (73-96) 77 (59-88) 75 (57-88) 56 (36-74) <0.001**
Median (IQR) Social-emotional**
function subscale score (0-100) 95 (83-100) 87 (75-95) 74 (58-86) 58 (50-79) 43 (33-60) <0.001**
* Chi-squared test, apart from ** Kruskal-Wallis test
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Table 3. Association of new Fear of cancer Recurrence (FoR) question with clinical and
personal characteristics.
(100) I have no
fear of recurrence
N=63










but I can usually
manage these
N=147







I am fearful all




% female 19% (12/63) 25% (63/249) 35% (52/147) 31% (8/26) 43% (12/28)
% aged <55 years at survey 6% (4/63) 12% (29/249) 16% (24/147) 36% (9/25) 29% (8/28)
% aged 55-64 25% (16/63) 32% (80/249) 42% (61/147) 40% (10/25) 39% (11/28)
% aged ≥65  68% (43/63) 56% (140/249) 42% (62/147) 23% (6/26) 32% (9/28) 
Median (IQR) age at survey 69 (62-74) 66 (61-73) 63 (57-69) 58 (51-66) 60 (54-67)
Late clinical stage 3-4 44% (24/55) 39% (93/236) 51% (71/138) 52% (13/25) 56% (15/27)
% Oral tumour site 30% (19/63) 41% (102/249) 29% (43/147) 35% (9/26) 29% (8/28)
% Oropharyngeal site 33% (21/63) 31% (76/249) 44% (65/147) 38% (10/26) 46% (13/28)
% laryngeal site 30%(19/63) 20% (51/249) 17% (25/147) 19% (5/26) 18% (5/28)
Primary treatment
%surgery only 53% (32/60) 55% (131/240) 43% (61/143) 42% (11/26) 39% (11/28)
%surgery & adjuvant 28% (17/60) 32% (77/240) 36% (51/143) 31% (8/26) 39% (11/28)
%RT-CT only 18% (11/60) 13% (32/240) 22% (31/143) 27% (7/26) 21% (6/28)
Median (IQR) months from treatment 36 (26-51) 38 (27-52) 33 (25-46) 30 (22-42) 38 (22-45)
% ever having RT as part of H&N cancer 56% (35/62) 57% (141/248) 71% (104/146) 65% (17/26) 89% (25/28)
% ever having CT as part of H&N cancer 15% (9/60) 12% (29/246) 26% (37/143) 27% (7/26) 39% (11/28)
% saying head and neck cancer ever
recurred (ever come back) 5% (3/62) 8% (20/242) 13% (18/144) 12% (3/26) 21% (6/28)
Age when left school/college/univeristy
<16 yrs 49% (30/61) 49% (118/243) 39% (56/142) 38% (10/26) 52% (14/27)
16-17 yrs 31% (19/61) 30% (73/243) 33% (47/142) 42% (11/26) 37% (10/27)
≥18 yrs 20% (12/61) 21% (52/243) 27% (39/142) 19% (5/26) 11% (3/27) 
* Chi-squared test, apart from ** Kruskal-Wallis test
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Figure 2. Correlation of the new single screening question about Fear of cancer Recurrence (FoR)
with the mean score of the 7 FoR questions in ‘The FoR Questionnaire’
Spearman correlation, rs=-0.82, p<0.001
